Bevacizumab

Generic Name: Bevacizumab

Brand Names: Avastin, Mvasi, Oyavas, Alymsys, Aybintio, Abevmy, Vegzelma, Onbevzi, Zirabev, Lytenava, Avzivi

Drug Type: Biotech

Chemical Formula: -

CAS Number: 216974-75-3

Unique Ingredient Identifier: 2S9ZZM9Q9V

Background: There is a great deal of evidence indicating that vascular endothelial growth factor (VEGF) is important for the survival and proliferation of cancer cells. VEGF plays an important role in angiogenesis, lymphangiogenesis, and tumor growth, which are all factors that contribute to its attractiveness as a therapeutic target for anti-cancer therapies.
...

Indication: As a vascular endothelial growth factor (VEGF) inhibitor, bevacizumab is used in several chemotherapy regimens to treat metastatic colorectal cancer; metastatic, unresectable, locally advanced or recurrent non-squamous non-small cell lung cancer; metastatic renal cell carcinoma; metastatic, persistent, or recurrent cervical cancer; primary peritoneal cancer;...

Associated Conditions: Metastatic Breast Cancer, Metastatic Cervical Cancer, Metastatic Colorectal Cancer (CRC), Metastatic Non-squamous Non Small Cell Lung Cancer, Metastatic Renal Cell Carcinoma ( mRCC), Persistent Cervical Cancer, Recurrent Cervical Cancer, Recurrent Glioblastoma, Relapsed Glioblastoma, Stage III Fallopian Tube Cancer, Stage III Ovarian Epithelial Cancer, Stage III Primary Peritoneal Cancer, Stage IV Fallopian Tube Cancer, Stage IV Ovarian Epithelial Cancer, Stage IV Primary Peritoneal Cancer, Locally advanced nonsquamous non-small cell lung cancer, Recurrent Non-Squamous Non-Small Cell Lung Cancer, Recurrent Platinum-Sensitive Epithelial Ovarian Cancer, Recurrent Platinum-resistant Epithelial Ovarian Cancer, Recurrent platinum drug resistant Fallopian tube cancer, Recurrent platinum drug resistant primary peritoneal cancer, Recurrent platinum sensitive primary peritoneal cancer, Recurrent platinum-sensitive fallopian tube cancer, Unresectable Non-Squamous Non-Small Cell Lung Cancer, Unresectable, advanced Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC)

Associated Therapies: First Line Chemotherapy, First or Second Line Therapy, Second Line Treatment

Clinical Trials

Bevacizumab and Erlotinib in the Treatment of Patients With Carcinoma of Unknown Primary Site

Phase 2

Completed

Conditions: Neoplasms, Unknown Primary

First Posted Date: 2005-09-19

Last Posted Date: 2010-09-17

Lead Sponsor: SCRI Development Innovations, LLC

Target Recruit Count: 50

Registration Number: NCT00193622

Irinotecan, Carboplatin and Radiation Therapy Followed by Bevacizumab in Limited Stage Small Cell Lung Cancer

Phase 2

Completed

Conditions: Lung Cancer

Interventions: Drug: Irinotecan
Drug: Carboplatin
Drug: Bevacizumab
Radiation: Radiation

First Posted Date: 2005-09-19

Last Posted Date: 2016-08-10

Lead Sponsor: SCRI Development Innovations, LLC

Target Recruit Count: 60

Registration Number: NCT00193375

Bevacizumab and Cetuximab in Combination With FOLFOX6 in Patients With Metastatic Colorectal Cancer

Phase 2

Completed

Conditions: Colon Cancer

Interventions: Drug: Bevacizumab
Drug: Cetuximab
Drug: 5-fluorouracil
Drug: Leucovorin
Drug: Oxaliplatin

First Posted Date: 2005-09-19

Last Posted Date: 2022-01-11

Lead Sponsor: SCRI Development Innovations, LLC

Target Recruit Count: 36

Registration Number: NCT00193219

Locations: 🇺🇸
St. Louis Cancer Care, Chesterfield, Missouri, United States
🇺🇸
Jackson Oncology Associates, Jackson, Mississippi, United States
🇺🇸
Chattanooga Oncology and Hematology Associates, Chattanooga, Tennessee, United States

and more 7 locations

OSI-774 and Bevacizumab in the Treatment of Patients With Metastatic Renal Cell Carcinoma

Phase 2

Completed

Conditions: Kidney Cancer

Interventions: Drug: OSI-774
Drug: Bevacizumab

First Posted Date: 2005-09-19

Last Posted Date: 2014-04-01

Lead Sponsor: SCRI Development Innovations, LLC

Target Recruit Count: 63

Registration Number: NCT00193154

Locations: 🇺🇸
Medical Oncology LLC, Baton Rouge, Louisiana, United States
🇺🇸
Grand Rapids Oncology Program, Grand Rapids, Michigan, United States

A Study of Rituximab and Bevacizumab in Patients With Follicular Non-Hodgkin's Lymphoma

Phase 2

Completed

Conditions: Lymphoma, Follicular

Interventions: Drug: Bevacizumab
Drug: Rituximab

First Posted Date: 2005-09-19

Last Posted Date: 2015-01-05

Lead Sponsor: SCRI Development Innovations, LLC

Target Recruit Count: 60

Registration Number: NCT00193492

Locations: 🇺🇸
Spartanburg Regional Medical Center, Spartanburg, South Carolina, United States
🇺🇸
Chattanooga Oncology Hematology Associates, Chattanooga, Tennessee, United States
🇺🇸
Oncology Hematology Care, Cincinnati, Ohio, United States

and more 19 locations

Safety and Efficacy Study Using Bevacizumab, Capecitabine and Oxaliplatin for Colorectal Cancer

Phase 2

Completed

Conditions: Cancer

Interventions: Drug: Bevacizumab
Drug: Capecitabine
Drug: Oxaliplatin

First Posted Date: 2005-09-15

Last Posted Date: 2016-07-12

Lead Sponsor: University of Pittsburgh

Target Recruit Count: 40

Registration Number: NCT00177307

Locations: 🇺🇸
University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States

Using Positron Emission Tomography to Evaluate the Effects of Bevacizumab on Intra-tumoral Pharmacokinetics of 5-fluorouracil in Metastatic Colorectal Cancer

Phase 2

Completed

Conditions: Colorectal Cancer
Neoplasm Metastasis

First Posted Date: 2005-09-14

Last Posted Date: 2009-11-01

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 20

Registration Number: NCT00165568

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States